阿西莫司急性升高超重及垂体功能减退患者GLP-1浓度
两项随机交叉研究显示,阿西莫司抑制脂解降低游离脂肪酸(FFA)后,超重者口服糖耐量试验中GLP-1曲线下面积增加一倍以上,垂体功能减退患者GLP-1升高约40%且胰岛素敏感性改善;大鼠肠道与L细胞体外实验未显示阿西莫司直接影响GLP-1分泌,提示机制为间接。
要点
- 阿西莫司降低FFA后超重者OGTT期间GLP-1 AUC增加一倍以上。
- 垂体功能减退患者阿西莫司改善胰岛素敏感性并升高GLP-1约40%。
- FFA与GLP-1浓度在两项试验中均呈负相关。
核心结论
- 阿西莫司治疗可升高超重受试者和垂体功能减退患者的全身GLP-1水平。
- 体外数据提示阿西莫司升高GLP-1的机制是间接的。
研究设计与样本
- 两项在人体进行的随机交叉研究。
- 参与者为健康超重受试者和垂体功能减退成年患者。
- 大鼠肠道进行动脉内和腔内灌注,L细胞与阿西莫司共孵育。
主要发现
- 临床试验中阿西莫司抑制FFA但对胰岛素无影响。
- 超重者OGTT后GLP-1曲线下面积增加一倍以上:4119 ± 607 pmol/L × min(阿西莫司)vs 1973 ± 375 pmol/L × min(对照),P = 0.004。
- 垂体功能减退患者胰岛素敏感性改善:4.7 ± 0.8 mg葡萄糖/kg/min(阿西莫司)vs 3.1 ± 0.5 mg葡萄糖/kg/min(对照),P = 0.005。
- 垂体功能减退患者GLP-1浓度升高约40%。
- 两项试验中FFA与GLP-1浓度均呈负相关。
临床怎么用
- 阿西莫司降低FFA可急性升高GLP-1,提示FFA与GLP-1分泌存在关联。
- 在垂体功能减退患者中阿西莫司同时改善胰岛素敏感性和升高GLP-1。
局限性
- 阿西莫司升高GLP-1的机制为间接,体外实验未证实L细胞直接作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity. The interplay between ambient free fatty acids (FFAs) and GLP-1 remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (also known as HCA2 and GPR109a) receptor. OBJECTIVE: To investigate whether lowering of serum FFA level with acipimox affects GLP-1 secretion. DESIGN: Two randomized crossover studies were performed in human subjects. Rat intestine was perfused intra-arterially and intraluminally, and l-cells were incubated with acipimox. PARTICIPANTS: The participants were healthy overweight subjects and hypopituitary adult patients. INTERVENTIONS: The overweight participants received acipimox 250 mg 60 minutes before an oral glucose test. The hypopituitary patients received acipimox 250 mg 12, 9, and 2 hours before and during the metabolic study day, when they were studied in the basal state and during a hyperinsulinemic euglycemic clamp. RESULTS: Acipimox suppressed FFA but did not affect insulin in the clinical trials. In overweight subjects, the GLP-1 increase after the oral glucose tolerance test (area under the curve) was more than doubled [4119 ± 607 pmol/L × min (Acipimox) vs 1973 ± 375 pmol/L × min (control), P = 0.004]. In hypopituitary patients, acipimox improved insulin sensitivity (4.7 ± 0.8 mg glucose/kg/min (Acipimox) vs 3.1 ± 0.5 mg glucose/kg/min (control), P = 0.005], and GLP-1 concentrations increased ~40%. An inverse correlation between FFA and GLP-1 concentrations existed in both trials. In rat intestine, acipimox did not affect GLP-1 secretion, and l-cells did not consistently express the putative receptor for acipimox. CONCLUSIONS: Acipimox treatment increases systemic GLP-1 levels in both obese subjects and hypopituitary patients. Our in vitro data indicate that the underlying mechanisms are indirect.
引用
- Vestergaard ET, Hjelholt AJ, Kuhre RE, et al. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients. J Clin Endocrinol Metab. 2019. PMID: 30726969. doi:10.1210/jc.2018-02503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。